Although dire predictions about the ruling on the biotech industry and health care have not come to pass, questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.
New optical technology is showing great promise in fighting cancer by targeting treatment but with minimal side effects to the patient.
A new study suggests that a noninvasive DNA stool test may enhance the efficacy of screening for colorectal cancer.
Although there are benefits to minimally invasive surgery, morcellation can increase the risk of tumor dissemination of uterine leiomyosarcomas.
Nanopharmaceutical formulations might allow newly widespread adoption of old anticancer agents, with reduced toxic effects.
Science presented at the 2014 Genitourinary Cancers Symposium focused on the clinical potential of prostate cancer biomarkers.
One recently published study found no mortality benefit to annual screening mammograms, but critics cry "foul."
HER2 screening and emetine dihydrochloride may offer patients with bladder cancer more effective treatment options.
The journal Science named cancer immunotherapy as "the breakthrough of the year"; but challenges still remain to overcome tumor immune suppression and genomic instability.
Although imatinib is the current standard of care for gastrointestinal stromal tumors, other therapies are proving to be effective treatments for the disease as well.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|